Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies
Infante, Jeffrey R., Tabernero, Josep, Burris, Howard A., Macarulla, Teresa, Martin, Michael, Liu, Yi, Jessen, Katti, Koczon, Ethel, Rommel, Christian, Klein, Pam M., Berk, Greg I., Bui, Lynne A., Gordon, Michael S.
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Get full text
Journal Article